The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer. The endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized CB1 and CB2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds.
There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged.
Bonni Goldstein, MD is the Medical Director of Canna-Centers, a California-based medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions. After years of working in the specialty of pediatric emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.
THIS CUSTOM STUDY WAS UNDERTAKEN BY STRAINPRINT TO UNDERSTAND POLYPHARMACY BEHAVIOR AND ATTITUDES AMONG 1,016 STRAINPRINT APP USERS, ALL OF WHOM ARE MEDICAL CANNABIS PATIENTS. DATA WERE COLLECTED FROM FEBRUARY 7, 2019, TO FEBRUARY 19, 2019.
Cannabinoids seem promising for treating the symptoms or progression of rheumatoid arthritis. But in the name of caution, many doctors prefer no treatment rather than trusting anecdotal reports about cannabis for arthritic pain. There’s hope that this attitude may change with upcoming research from a group of Danish scientists who recently pre-registered a double-blind randomized controlled trial of cannabinoids’ effects on arthritic pain and ankylosing spondylitis.
Cannabidiol, or CBD, already being researched and used for anxiety, insomnia, epilepsy and pain, may be the next superbug fighter for resistant infections, a new study suggests.